Purpose: Leptomeningeal disease in prostate adenocarcinoma is very rare. Solitary leptomeningeal recurrence from prostate adenocarcinoma has only been previously reported once in the published literature. Methods and Materials: A 63-year-old man with high-risk prostate cancer was treated in a phase I-II trial with androgen deprivation, radiation therapy, and cytotoxic gene therapy. He initially had biochemical control but experienced solitary leptomeningeal recurrence 47 months after diagnosis. Results: He received androgen deprivation, radiation therapy to the lumbar and sacral spine, and stereotactic radiosurgery to 3 intracranial foci of disease. He died 14 months after leptomeningeal recurrence. Autopsy showed diffuse spinal leptomeningeal disease, leptomeningeal based intracranial lesions, and no other metastasis. Conclusions: The cause for solitary leptomeningeal recurrence in this patient is unknown. Although there may be many possible mechanisms, we speculate that it could be related to his initial treatment with cytotoxic gene therapy along with radiation therapy and androgen deprivation.
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging